Segment Information (Tables)

12 Months Ended

Dec. 31, 2014

Segment Information

Schedule of net revenues, cost of product sales and gross profit for each commercial product

Net revenues, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):

	Remodulin		Tyvaso		Adcirca		Orenitram		Total
Year Ended December 31, 2014
Net revenues	$	553,728	$	463,067	$	221,471	$	41,267	$	1,279,533
Cost of product sales		47,327		57,442		13,495		7,619		125,883
Gross profit	$	506,401	$	405,625	$	207,976	$	33,648	$	1,153,650
Year Ended December 31, 2013
Net revenues	$	491,179	$	438,793	$	176,972	$	—	$	1,106,944
Cost of product sales		59,314		60,831		10,982		—		131,127
Gross profit	$	431,865	$	377,962	$	165,990	$	—	$	975,817
Year Ended December 31, 2012
Net revenues	$	457,969	$	325,614	$	122,540	$	—	$	906,123
Cost of product sales		57,618		53,825		7,854		—	$	119,297
Gross profit	$	400,351	$	271,789	$	114,686	$	—	$	786,826

Schedule of net revenues from external customers by geographic area

Net revenues from external customers by geographic area are as follows (in thousands):

Year Ended December 31,	2014		2013		2012
United States	$	1,180,759	$	1,032,435	$	846,611
Rest-of-World(1)		107,760		84,549		69,465
Total	$	1,288,519	$	1,116,984	$	916,076

(1) Primarily Europe.

Schedule of long-lived assets (property, plant and equipment) located by geographic area

        Long-lived assets (property, plant and equipment) located by geographic area are as follows (in thousands):

Year Ended December 31,	2014		2013		2012
United States	$	462,377	$	442,673	$	425,585
Rest-of-World(1)		16,044		22,277		28,100
Total	$	478,421	$	464,950	$	453,685

(1) Facilities principally located in the United Kingdom.